- Home
- PETS vs ZURA Comparison
PETS vs ZURA Comparison
Compare PETS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ZURA
- Stock Information
- Founded
- PETS 1996
- ZURA 2022
- Country
- PETS United States
- ZURA United States
- Employees
- PETS N/A
- ZURA N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- ZURA Health Care
- Exchange
- PETS Nasdaq
- ZURA Nasdaq
- Market Cap
- PETS 58.9M
- ZURA 69.9M
- IPO Year
- PETS N/A
- ZURA N/A
- Fundamental
- Price
- PETS $2.82
- ZURA $1.96
- Analyst Decision
- PETS Sell
- ZURA Buy
- Analyst Count
- PETS 1
- ZURA 10
- Target Price
- PETS $3.20
- ZURA $12.67
- AVG Volume (30 Days)
- PETS 92.2K
- ZURA 309.4K
- Earning Date
- PETS 11-05-2025
- ZURA 11-06-2025
- Dividend Yield
- PETS N/A
- ZURA N/A
- EPS Growth
- PETS N/A
- ZURA N/A
- EPS
- PETS 0.02
- ZURA N/A
- Revenue
- PETS $247,010,000.00
- ZURA N/A
- Revenue This Year
- PETS N/A
- ZURA N/A
- Revenue Next Year
- PETS N/A
- ZURA N/A
- P/E Ratio
- PETS $164.97
- ZURA N/A
- Revenue Growth
- PETS N/A
- ZURA N/A
- 52 Week Low
- PETS $2.72
- ZURA $0.97
- 52 Week High
- PETS $6.85
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- PETS 50.01
- ZURA 52.64
- Support Level
- PETS N/A
- ZURA $1.88
- Resistance Level
- PETS $3.08
- ZURA $2.19
- Average True Range (ATR)
- PETS 0.10
- ZURA 0.15
- MACD
- PETS -0.12
- ZURA -0.04
- Stochastic Oscillator
- PETS 88.68
- ZURA 20.00
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.